These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3232800)

  • 1. Altered aminoglycoside pharmacokinetics in the critically ill.
    Beckhouse MJ; Whyte IM; Byth PL; Napier JC; Smith AJ
    Anaesth Intensive Care; 1988 Nov; 16(4):418-22. PubMed ID: 3232800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care.
    Niemiec PW; Allo MD; Miller CF
    Arch Surg; 1987 Feb; 122(2):207-12. PubMed ID: 3813869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group.
    Dorman T; Swoboda S; Zarfeshenfard F; Trentler B; Lipsett PA
    Surgery; 1998 Jul; 124(1):73-8. PubMed ID: 9663254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
    Grucz TM; Kruer RM; Bernice F; Lipsett PA; Dorman T; Sugrue D; Jarrell AS
    Surg Infect (Larchmt); 2020 Dec; 21(10):859-864. PubMed ID: 32302517
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients.
    Dasta JF; Armstrong DK
    Crit Care Med; 1988 Apr; 16(4):327-30. PubMed ID: 3349791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gentamicin volume of distribution in critically ill septic patients.
    Triginer C; Izquierdo I; Fernández R; Rello J; Torrent J; Benito S; Net A
    Intensive Care Med; 1990; 16(5):303-6. PubMed ID: 2212254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoglycoside pharmacokinetics in African-Americans with normal renal function.
    Oparaoji EC; Siram S; Elemihe U; Mezghebe HM; Cho T; Bashiri M; Piedrahita K; Pipalla RS
    J Clin Pharm Ther; 1998 Jun; 23(3):191-7. PubMed ID: 9831970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing use of aminoglycosides in the critically ill.
    Rea RS; Capitano B
    Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal aminoglycoside therapy following the sepsis: how much is too much?
    Mahmoudi L; Niknam R; Mousavi S; Ahmadi A; Honarmand H; Ziaie S; Mojtahedzadeh M
    Iran J Pharm Res; 2013; 12(2):261-9. PubMed ID: 24250599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside dosing considerations in intensive care unit patients.
    Watling SM; Dasta JF
    Ann Pharmacother; 1993 Mar; 27(3):351-7. PubMed ID: 8267695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inadequacy of standard aminoglycoside loading doses in acutely ill patients.
    Chelluri L; Jastremski MS
    Crit Care Med; 1987 Dec; 15(12):1143-5. PubMed ID: 3677767
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients.
    Denaro CP; Ravenscroft PJ
    Aust N Z J Med; 1987 Oct; 17(5):526-32. PubMed ID: 3446165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.
    Mann HJ; Fuhs DW; Awang R; Ndemo FA; Cerra FB
    Clin Pharm; 1987 Feb; 6(2):148-53. PubMed ID: 3665367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.